Roivant reports Q1 net loss of $290.6 million, up from $273.9 million a year earlier
Roivant reported a net loss of $290.6 million for the quarter ended June 30, 2026, up from $273.9 million a year earlier, on revenue of $1.4 million versus $2.2 million. Net loss per share narrowed to $0.26 from $0.33, and the net loss attributable to Roivant Sciences Ltd. was $189.8 million versus $223.4 million, while R&D and G&A expenses both rose.
Key points
- Net loss per common share was $0.26 versus $0.33 a year earlier; non-GAAP net loss was $243.7 million versus $170.1 million.
- R&D expenses rose $49.1 million to $202.0 million; G&A expenses rose $31.5 million to $165.5 million.
- Roivant repurchased 7.3 million common shares for about $208.7 million in the quarter.
- Cash, cash equivalents, restricted cash and marketable securities were $3.9 billion at June 30, 2026, excluding the $950 million Moderna payment received in July 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.